Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is a clinical-stage immuno-oncology company advancing novel therapies targeting the CD47 checkpoint pathway. This page provides investors and industry professionals with essential updates on evorpacept development, strategic partnerships, and clinical trial progress.
Access consolidated news about ALXO’s innovative approach to enhancing cancer treatment through engineered CD47 blockade. Stay informed about regulatory milestones, research collaborations, and financial disclosures that shape the company’s trajectory in oncology drug development.
Key updates include clinical trial results for evorpacept combination therapies, FDA communications, and scientific presentations. All content is curated to support informed analysis of ALXO’s position in the competitive immuno-oncology landscape.
Bookmark this page for streamlined access to verified ALX Oncology announcements. Check regularly for developments in hematologic and solid tumor research programs leveraging the company’s proprietary protein engineering platform.
ALX Oncology (NASDAQ:ALXO) has initiated its Phase 1 clinical trial of ALX2004, a potential first-in-class antibody-drug conjugate (ADC) targeting EGFR-expressing solid tumors. The first patient has been dosed in the open-label multicenter study (NCT07085091).
The trial will evaluate ALX2004 in patients with advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), and colorectal cancer (CRC). The study comprises Phase 1a dose escalation, dose exploration, and Phase 1b dose expansion portions.
ALX2004 features an optimized design with an affinity-tuned EGFR antibody and proprietary topoisomerase I inhibitor payload. Preclinical data has shown superior stability, dose-dependent activity, and a favorable safety profile without significant EGFR-related skin toxicity. Initial safety data is expected in the first half of 2026.
ALX Oncology (NASDAQ:ALXO) reported significant advances in its clinical programs during Q2 2025. A key highlight was the identification of CD47 expression as a predictive biomarker in HER2+ gastric cancer patients, where CD47-high patients showed a 65% objective response rate with evorpacept combination therapy versus 26% in the control group.
The company has updated its ASPEN-Breast trial design to a single-arm study incorporating CD47 biomarker strategy, with interim data expected in Q3 2026. Additionally, ALX2004, their novel ADC candidate for EGFR-expressing tumors, is set to begin patient dosing in August 2025.
Financially, ALX reported $83.5 million in cash as of June 30, 2025, extending runway into Q1 2027. Q2 net loss was $25.9 million ($0.49 per share), improved from $39.4 million in Q2 2024.
ALX Oncology (NASDAQ: ALXO), a clinical-stage biotechnology company focused on developing cancer therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.
The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the event through a webcast or by dialing 1-877-407-0752 (US) or +1-201-389-0912 (International). Presentation slides and an archived recording will be available on the company's website.
ALX Oncology (NASDAQ: ALXO) has announced a webcast event scheduled for May 20, 2025, focusing on ALX2004, their novel antibody-drug conjugate (ADC). The event will showcase ALX2004's mechanism of action, preclinical data, and clinical development strategy following FDA's IND clearance earlier this year.
ALX2004, developed in-house using the company's proprietary topoisomerase I inhibitor payload platform, is designed to target EGFR-expressing tumors. The presentation will feature key executives including CEO Jason Lettmann, CMO Alan Sandler, and VP of Antibody Technologies Marija Vrljic, who will discuss planned clinical progress and updates.
ALX Oncology Holdings (Nasdaq: ALXO), a clinical-stage biotechnology company focused on developing cancer therapies, has announced it will release its first quarter 2025 financial results on Thursday, May 8th, 2025, before the market opens. The company has specified that it will not hold a conference call to discuss the results.
ALX Oncology (ALXO) has announced final results from a Phase 1 trial evaluating evorpacept in combination with rituximab and lenalidomide (R2) for B-cell non-Hodgkin lymphoma. The study demonstrated promising outcomes with 83% complete response rate in indolent NHL patients, significantly higher than the 34% historical rate with R2 alone.
The trial enrolled 20 patients, including 18 with indolent and 2 with aggressive R/R B-NHL. Key findings include:
- Two-year progression-free survival rate of 69%
- Two-year overall survival rate of 84%
- 90% best overall response rate
- Well-tolerated treatment with no dose-limiting toxicities
The Phase 2 portion of the trial in previously untreated indolent NHL patients has completed enrollment. Results will be presented at the AACR 2025 Annual Meeting.
ALX Oncology (ALXO) announced that its Phase 2 ASPEN-03 and ASPEN-04 clinical trials for evorpacept in combination with Merck's KEYTRUDA® did not meet primary endpoints for treating head and neck squamous cell carcinoma (HNSCC). The trials evaluated improved objective response rates compared to historical controls.
Despite encouraging trends in ASPEN-03, the company will discontinue pursuing evorpacept with pembrolizumab in HNSCC. However, ALX Oncology will continue multiple clinical trials of evorpacept combined with anti-cancer antibodies, citing positive results in HER2-positive gastric and breast cancer trials.
The company remains focused on evorpacept's primary mechanism of action - blocking the CD47 'don't eat me' signal on cancer cells - and its ongoing evaluation in colorectal cancer, breast cancer, non-Hodgkin lymphoma, and multiple myeloma trials.
FAQ
What is the current stock price of Alx Oncology Holdings (ALXO)?
What is the market cap of Alx Oncology Holdings (ALXO)?
